VERRICA PHARMACEUTICALS INC. - COMMON STOCK

Verrica Provides Business and Operational Update

20 Dec 2024 06:00:00 By Nasdaq GlobeNewswire

Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

09 Dec 2024 15:15:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan

06 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Verrica Announces Pricing of $42.0 Million Public Offering

21 Nov 2024 06:30:00 By Nasdaq GlobeNewswire

Verrica Announces Proposed Public Offering

20 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition

04 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference

24 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

02 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York

04 Sep 2024 06:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

14 Aug 2024 06:45:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma

14 Aug 2024 06:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024

06 Aug 2024 06:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.

01 Jul 2024 06:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

30 May 2024 15:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

15 May 2024 06:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results

13 May 2024 06:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Present at Upcoming Investor Conferences

09 May 2024 06:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024

08 May 2024 06:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

02 Apr 2024 06:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA

26 Mar 2024 06:30:00 By Nasdaq GlobeNewswire